Physician profile
Benjamin L Watson
NPI 1124027842
$14,408.87
in general payments reported to CMS, 2019-2025
49 companies · $2,448 in 2025
The $2,448 reported for 2025 was more than what 95% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,201 · 2020: $1,017 · 2021: $2,146 · 2022: $2,134 · 2023: $2,220 · 2024: $3,243 · 2025: $2,448.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $2,750 · Food and Beverage: $2,155 · Gift: $2,006 · Education: $1,000.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $2,750.00 |
| Food and Beverage | $2,154.66 |
| Gift | $2,006.20 |
| Education | $1,000.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $6,387.31 | 2019-2025 | |
| E.R. Squibb & Sons, L.L.C. | $3,021.49 | 2021-2025 | Eliquis |
| Intuitive Surgical, INC. | $1,035.18 | 2024-2025 | |
| Novartis Pharmaceuticals Corporation | $744.60 | 2019-2025 | |
| Novo Nordisk INC | $741.85 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $288.56 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Amgen INC. | $225.97 | 2019-2025 | Repatha, Otezla, Repatha |
| Astrazeneca Pharmaceuticals LP | $184.07 | 2019-2023 | |
| Abbvie INC. | $183.20 | 2021-2025 | Qulipta |
| Boehringer Ingelheim Pharmaceuticals, INC. | $138.75 | 2019-2025 | Jardiance |
| Dexcom, INC. | $129.30 | 2024-2025 | Dexcom G6 Transmitter |
| Bayer Healthcare Pharmaceuticals INC. | $120.60 | 2021-2025 | |
| Esperion Therapeutics, INC. | $105.34 | 2020-2024 | Nexletol |
| Stryker Corporation | $102.03 | 2021 | |
| Mannkind Corporation | $81.52 | 2021 |
Show all 49 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Benjamin Watson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.